Back to News

Borealis and Borouge introduce Borealis Bormed™ PL8830-PH, the first controlled plastomers solution for the healthcare industry

Because we care: Borealis Bormed™ pharmaceutical packaging

Borealis and Borouge, leading providers of innovative, value-creating plastics solutions, announce the expansion of the dedicated Borealis Bormed™ brand portfolio of polyethylene and polypropylene (PP) products. The introduction of the first controlled plastomers solution for the global healthcare market, Bormed™ PL8830-PH, will take place at the CPhI in Madrid in October. As a controlled plastomers grade, Bormed PL8830-PH pushes the envelope when it comes to polyolefins performance characteristics for healthcare applications. Bormed PL8830-PH is part of the Bormed™ Concept service package encompassing Service, Commitment, and Conformance, and thus underscores the Borealis and Borouge commitment to the healthcare industry.

Because we care: ensuring security of supply for medical grades

The healthcare market depends on the reliable and secure supply of controlled raw materials which must fulfil especially demanding standards in regard to safety, biocompatibility, toxicity and more. The security of supply drives the risk management decision-making process along the entire pharmaceutical value chain.

The enlargement of the Bormed portfolio to include Bormed PL8830-PH means that Borealis now has one of the largest product offerings for the global healthcare market. It is currently the only raw material supplier to offer a material that can bridge the gap between thermoplastics and elastomers. Importantly, the Bormed Concept ensures that customers can rely on security of supply of raw materials, in both the short and long term, which are compliant with European, US Pharmacopeia, and ISO standards.

Enlarged Borealis Bormed portfolio pushes performance in healthcare applications

Bormed PL8830-PH is an ethylene-based, octene-1 plastomer. Because it is a reactor polymer, it boasts the very highest and most consistent quality. Overall, it exhibits excellent purity and cleanliness. It offers enhanced compatibility with PP, easy processing, clarity, and flexibility on an elastomers level. Bormed PL8830-PH has been specifically developed to be used as a versatile blend partner along with other polyolefins in film, extrusion, and moulding applications and offers any number of advantages, from manufacturer to end user:

  • High-performance: When blended with the other controlled resins of the Bormed portfolio, Bormed PL8830-PH offers tailored performance attributes to meet the most stringent and demanding healthcare application requirements.
  • High pack integrity: Borealis Bormed PL8830-PH makes it possible to achieve very high packaging integrity, even at low temperatures; for example, this helps avoid damage to a pouch if accidently dropped, and ensures a tight seal to avoid contamination of contents.
  • Simplified processes: Borealis Bormed PL8830-PH contains very low levels of antioxidants but no other additives, thus simplifying the effort required to evaluate potential interaction between the application or packaging material itself, and its contents
  • Potential cost savings: Using Borealis Bormed PL8830-PH helps reduce manufacturing costs because it allows for the significant reduction in the number of non-polyolefin impact modifiers used to achieve performance properties like impact strength. 
  • Enhanced sustainability: Using Borealis Bormed PL8830-PH instead of non-polyolefinic blend components yields a mono-material solution which is more easily recyclable. This is an especially attractive proposition for the healthcare value chain in the EU and other regions where implementation of circular economy principles is becoming a priority. 

The principle application of Bormed PL8830-PH is as a modifier in pharmaceutical film, for example for medical fluid bags. In pharmaceutical packaging it is especially suited for use in pouch systems because it allows for reduced use of non-polyolefin impact modifiers, as well as other compounds and elastomers. Possible applications include:

  • Pharmaceutical primary packaging: IV bags, Continuous Ambulatory Peritoneal Dialysis (CAPD), pouch systems, Active Pharmaceutical Ingredient (API) bags
  • Pharmaceutical secondary packaging
  • Film for medical device packaging
  • Bioreactors

“By enlarging our Bormed portfolio with the first-ever controlled plastomers solution, we are also helping our customers expand the range of what is possible in healthcare applications,” states Nina Ackermans, Borealis Head of Marketing Advanced Products. “We will continue to anticipate the needs and challenges of the industry by offering excellent service as well as innovative and reliable solutions.”

Visit Borealis and Borouge at the
- CPhI in Madrid, Spain from 9-11 October 2018, in Hall 4, Stand 4D30; and at the
- COMPAMED trade fair in Düsseldorf, Germany, from 12-15 November 2018


For further information please contact:

Virginia Mesicek
External Communications Manager
tel.: +43 1 22 400 772 (Vienna, Austria)

Because we care: Borealis Bormed™ pharmaceutical packaging

Borealis and Borouge introduce Borealis Bormed™ PL8830-PH, the first controlled plastomers solution for the healthcare industry English, German
Because we care: Borealis Bormed™ pharmaceutical packaging
Borealis Bormed™ PL8830-PH with Soft PPs: Pushing the performance envelope for polyolefins in pharmaceutical packaging Photo: © Borealis
Media Contact
Group Media desk
Virginia Wieser, Lena Lehner
+43 1 22 400 899 (Vienna, Austria)

Latest News

Media Release – 29/11/2023

Borealis to acquire Integra Plastics AD, an advanced mechanical recycling player based in Bulgaria

Read more

Media Release – 27/11/2023

Borealis extends its collaboration with prominent educational and social institutions in the United Arab Emirates

Read more

News – 14/11/2023

Update on the Kallo case

Read more

Media Release – 02/11/2023

Borealis expands its mechanically recycled plastic compounding capacity with closing the acquisition of Rialti S.p.A.

Read more

News – 31/10/2023

Five Years of Support for the Ellen MacArthur Foundation’s Global Commitment

Read more

News – 30/10/2023

Borealis supports European plastics industry roadmap for a circular and net zero transformation

Read more

News – 30/10/2023

Borealis-backed SPIRIT program targets a breakthrough in CO2 direct capture

Read more

Media Release – 24/10/2023

Borealis signs first long-term power purchase agreement with Alpiq to supply renewable energy to Borealis production operations in Finland

Read more

Media Release – 23/10/2023

Winners of the Borealis Scientific Innovation Award recognized during Borealis Innovation Day

Read more